Speaking Faculty and Scientific Advisors

• Samuel C. Blackman, M.D., Ph.D., Associate Director, Experimental Medicine, MERCK
• Christine Brauer, President, BRAUER DEVICE CONSULTANTS, former scientific reviewer at the Center for Device Evaluation, FDA
• Thomas Goetz, MPH, Executive Editor, WIRED MAGAZINE Author, The Decision Tree
• Abdel Halim, PharmD, PhD, DABCC-CC, DABCC-TOX, DABCC-MD, FACB, Director, Clinical Biomarkers, DAIICHI SANKYO PHARMA DEVELOPMENT
• Jason Hill, PhD, Director, Strategic Business and Operations, Oncology, QUINTILES
• Kenneth I Kaitin, PhD, Director and Professor of Medicine, TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT, TUFTS UNIVERSITY
• Ann Kapoun, PhD, Director, Translational Medicine, ONCOMED PHARMACEUTICALS
• Stephen Furlong, PhD, Senior Director & Safety Science Lead, ASTRAZENECA
• Marcia Lewis, PhD, Vice President, Biomarker Development, PGXHEALTH
• Howard Mackey, Senior Statistical Scientist, Clinical Biostatistics, GENENTECH
• C. Hyung Park, PhD, former Director, Biomarker Outsourcing, Clinical Translational Medicine, PFIZER
• Terry Robins, Ph.D., Director, Biomarker Research & Development, Clinical Trials, QUEST DIAGNOSTICS
• Heather R. Sanders, PhD, Principal Scientist, Oncology R&D, QUEST DIAGNOSTICS NICHOLS INSTITUTE
• Shabnam Tangri, Director, Clinical Sciences and Technology, BIOGEN IDEC
• Grant Williams, MD, WILLIAMS CANCER DRUG CONSULTING, LLC, former CDER Oncology Medical reviewer, Team Leader, Deputy Division Director, FDA